Shares of DexCom (NASDAQ:DXCM) on Thursday surged more than 14% in extended trading, after the medical device maker raised its full year revenue guidance and announced a new $500M share buyback. DXCM ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock. DexCom makes continuous glucose monitoring (CGM) devices, which are crucial for ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
Medical device company DexCom (NASDAQ:DXCM) announced in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to ...
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...
DexCom (NASDAQ:DXCM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their ...
DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus Estimate of 57 cents by 7%. The company reported earnings of 45 cents per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback